Changes in Semaglutide Fills Following Expanded FDA and Medicare Policies

Am J Manag Care. 2026 Jul;32(7):392-395. doi: 10.37765/ajmc.2026.89983.ABSTRACTOBJECTIVES: The glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide has several branded versions, including Wegovy, which was initially approved for chronic weight management. In March 2024, the FDA expanded W

C Christopher Scannell

Case 353

Radiology. 2026 Aug;320(2):e260672. doi: 10.1148/radiol.260672.ABSTRACTHistory An 8-month-old term-born female infant presented to the pediatric emergency department with progressively increasing respiratory distress and episodic hypoxic spells for 2 months. Antenatal and birth histories were uneven

S Stuti Chandola

Cluster-Randomized Trials - Insights from Cardiovascular Prevention

NEJM Evid. 2026 Sep;5(9):EVIDctw2600148. doi: 10.1056/EVIDctw2600148. Epub 2026 Aug 25.ABSTRACTAbstractCluster-randomized trials are increasingly relevant to the evaluation of preventive and treatment strategies for chronic disease, especially when interventions are delivered through groups, practic

R Ravi Vazirani

Associations of cumulative exposure and control patterns of the single-point insulin sensitivity estimator with incident cardiovascular disease in middle-aged and older Chinese adults with dysglycemia

Nutr Hosp. 2026 Aug 7. doi: 10.20960/nh.06792. Online ahead of print.ABSTRACTOBJECTIVE: the single-point insulin sensitivity estimator (SPISE) is a novel insulin resistance marker; however, the longitudinal impacts of cumulative SPISE (cuSPISE) and its control patterns on cardiovascular disease (CVD

H Hao Li

Building Nutrition science ‒ Reflections on research, leadership, and legacy

Nutr Hosp. 2026 Aug 7. doi: 10.20960/nh.07049. Online ahead of print.ABSTRACTNutrition science has undergone a remarkable transformation over the past four decades, evolving from a relatively underrecognized discipline into a cornerstone of biomedical research and chronic disease prevention. This ar

J Jordi Salas-Salvadó

Therapeutic effect of Fuzheng Yixin decoction on cardiac insufficiencythe soluble guanylyl cyclase-cyclic guanosine monophosphate-protein kinase G pathway in a doxorubicin-induced dilated cardiomyopathy rat model

J Tradit Chin Med. 2026 Aug;46(4):854-863. doi: 10.19852/j.cnki.jtcm.20260514.002.ABSTRACTOBJECTIVE: To investigate the effect of Fuzheng Yixin decoction (, FZYX) and explore its underlying mechanisms in doxorubicin-induced dilated cardiomyopathy (DCM) rat model.METHODS: Sprague-Dawley rats were int

S Sang Xiuxiu

Paeonol's protective effects on H9C2 cells against hypoxia/ reoxygenation injury through the hypoxia-inducible factor 1-alpha/B-cell lymphoma-2/adenovirus E1B 19 kDa interacting protein 3 signaling pathway

J Tradit Chin Med. 2026 Aug;46(4):779-787. doi: 10.19852/j.cnki.jtcm.2026.04.001.ABSTRACTOBJECTIVE: To elucidate the cytoprotective capacity of paeonol (PAE) against hypoxia/reoxygenation (H/R) injury in H9C2 cardiomyoblasts and to clarify its regulatory effects on the hypoxia-inducible factor 1-alp

Z Zhao Chengguo